Amparo García

University of Barcelona, Barcino, Catalonia, Spain

Are you Amparo García?

Claim your profile

Publications (3)5.58 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: A prospective virologic follow-up of solid organ transplant patients was designed to determine the usefulness of antigenemia and viremia as virologic markers for the diagnosis of cytomegalovirus (CMV) infections, and also for monitoring CMV disease and therapy control. A total of 629 blood samples from 127 patients (60 liver, 47 kidney, and 20 heart transplant recipients) were studied by tube and shell vial cultures, and by antigenemia assay. This later was carried out by an indirect immunofluorescent assay method for formalin-fixed cytospin slides containing 2 x 10(5) leukocytes, using a monoclonal antibody directed against the CMV pp65 antigen. CMV was detected by at least one of the three methods in 238 specimens (37.8%) from a total of 63 patients. The antigenemia assay was positive in 215 (90.3% of positive samples). A total of 94 samples were detected only by this marker, which occurred either in samples with low positive counts (70.2% with antigenemia counts < 10 positive cells/10(5) leukocytes) or in specimens from treated patients. There were 30 episodes of CMV disease in 23 patients. Antigenemia was positive in all these episodes, 27 of them with counts > 20 positive cells/10(5) leukocytes. With this cut-off, positive and negative predictive values for symptomatic CMV infection were 100% and 97.2%, respectively. The antigenemia assay is a rapid, sensitive, specific, and early marker of CMV infection in transplantees. Cultures became negative with antiviral therapy while remaining antigenemia detectable. There was an association between highest quantitative antigenemia test results and clinical symptoms in our patients. In its quantitative version, the assay is useful to detect symptomatic infection and appears to be a helpful tool in managing patients at risk and in guiding antiviral therapy.
    Diagnostic Microbiology and Infectious Disease 01/1996; 24(1):19-24. DOI:10.1016/0732-8893(95)00248-0 · 2.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A selected sample of 492 strains of Streptococcus pneumoniae (175 susceptible, 142 intermediately resistant, and 175 highly resistant to penicillin) isolated from adult patients in Bellvitge Hospital, Barcelona, Spain, was tested for susceptibility to 16 antibiotics using a microdilution broth method. Imipenen, rifampin, vancomycin, cefpirome, cefotaxime, and amoxicillin were the most active antibiotics against penicillin-resistant pneumococci. The strains with intermediate or high resistance to penicillin exhibited a significantly greater percentage of resistance (P ⩽ 0.05) to erythromycin, clindamycin, tetracycline, chloramphenicol, and cotrimoxazole than penicillin-susceptible pneumococci. No resistance to third-generation cephalosporins was detected among penicillin-susceptible strains, whereas 1.4% of intermediately resistant strains and 13.2% of penicillin-resistant strains showed minimal inhibitory concentrations of cefotaxime ⩾ 2 μg/mL.
    Current Therapeutic Research 01/1996; 57(13):57-64. DOI:10.1016/S0011-393X(96)80100-7 · 0.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A total of 102 blood samples were used in a prospective parallel and blind study to evaluate three commercially available anti-pp65 monoclonal antibodies for cytomegalovirus antigenemia assay, at the dilutions recommended by their manufacturers. Cytomegalovirus was detected in 42 samples (41.2%), by either culture (32 samples; 76.2% of positive samples) or antigenemia (38 samples; 90.6%). Of the antigenemia-positive samples, 37 were detected by Monofluo kit CMV, which showed statistically significant differences when compared with the other reagents (Biosoft 1C3 and Clonab C10/C11), in either positivity rates (P < 0.004) or positive cell counts (P < 0.001). This reagent also gave better results in fluorescence quality than 1C3 and C10/C11. However, technical differences were not reflected in the clinical relevance of the antigenemia results.
    Diagnostic Microbiology and Infectious Disease 01/1995; 21(1):21-5. DOI:10.1016/0732-8893(94)00144-L · 2.57 Impact Factor